Adoptive Immunotherapy Following Umbilical Cord Blood Transplantation Using The Sleeping Beauty System and Artificial Antigen Presenting Cells To Generate.

Slides:



Advertisements
Similar presentations
Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):
Advertisements

Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation  Li Mei Poon, Amir Hamdi, Rima.
Allogeneic Stem Cell Transplantation (Allo-SCT) for the Treatment of T-Cell Acute Lymphoblastic Leukemia (T-ALL); Evaluation of Minimal Residual Disease.
The beauty of TLR agonists for CTCL
Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.
Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation  Li Mei Poon, Amir Hamdi, Rima.
Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: donor type matters by Maha El-Zimaity, Rima Saliba, Kawah Chan, Munir Shahjahan,
A Prospective Randomized Trial of Buffy Coat Versus CD34-Selected Autologous Bone Marrow Support in High-Risk Breast Cancer Patients Receiving High-Dose.
Adaptive Immunotherapy with Autologous CD25-Depleted and CD3/CD28-Costimulated T-Cells Enhances Lymphocyte Recovery after Cyclophosphamide - Fludarabine.
Next-generation leukemia immunotherapy
by Venetia Bigley, Laura E. Spence, and Matthew Collin
Ulas D. Bayraktar, Denái R. Milton, Elizabeth J
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,
High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphoid.
Figure 1 Chimeric antigen receptor (CAR) structures
Antibody-modified T cells: CARs take the front seat for hematologic malignancies by Marcela V. Maus, Stephan A. Grupp, David L. Porter, and Carl H. June.
Clofarabine ± Fludarabine with Once Daily i. v
T regulatory cells turn on T regulatory cells
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.
Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation by Takuya Sekine,
T-Cell Acute Lymphoblastic Lymphoma (T-LBL) and Stem Cell Transplantation (SCT): A Comparison of Outcomes with T-Cell Acute Lymphoblastic Leukemia (T-ALL) 
In Utero Depletion Of Fetal Host Hematopoietic Stem Cells Improves Engraftment Following Neonatal Transplantation In Mice by Chris Derderian, Charmin King,
Figure 1 CAR-T-cell design
Rare cells predict GVHD
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Lymphoma spread? Target CD47-SIRPα!
Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes 
Long-Term Follow-Up of Patients Who Experienced Graft Failure Postallogeneic Progenitor Cell Transplantation. Results of a Single Institution Analysis 
Chemokines and chemokine receptors: here, there, and everywhere
Umbilical Cord Blood Transplantation Supported by Third-Party Donor Cells: Rationale, Results, and Applications  Koen Van Besien, Hongtao Liu, Nitin Jain,
Outcomes of Patients with Myeloid Malignancies Treated with Allogeneic Hematopoietic Stem Cell Transplantation from Matched Unrelated Donors Compared.
Immunotherapy for acute lymphoblastic leukemia: from famine to feast
Allogeneic Stem Cell Transplantation (Allo-SCT) for the Treatment of T-Cell Acute Lymphoblastic Leukemia (T-ALL); Evaluation of Minimal Residual Disease.
Receiving Information on Fertility- and Menopause-Related Treatment Effects among Women Who Undergo Hematopoietic Stem Cell Transplantation: Changes in.
Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen–
Central Nervous System Relapse in Adults with Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation  Amir Hamdi, Raya.
Xiuyan Wang, Isabelle Rivière  Molecular Therapy - Oncolytics 
Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia  Fleur M. Aung,
Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning.
Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia:
FGF-2 signaling mediates expansion of HSPCs
Cell-Based Therapy Using Umbilical Cord Blood for Novel Indications in Regenerative Therapy and Immune Modulation: An Updated Systematic Scoping Review.
The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation  Rohtesh S. Mehta, Antonio Di Stasi, Borje S.
Impact of t(11;14)(q13;q32) on the Outcome of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma  Koji Sasaki, Gary Lu, Rima M. Saliba,
Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing.
Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic.
by Stefan O. Ciurea, Maria Cecilia Borges Bittencourt, Denái R
Dose Intensification of Busulfan in the Preparative Regimen Is Associated with Improved Outcomes: A Phase I/II Controlled, Randomized Study  Simrit Parmar,
Pauline Damien, David S. Allan 
Automated Production of Clinical-Grade CMV-Specific T Cells to Implement Immunotherapy at the Bedside  Priti Tewari, MD, Pappanaicken R. Kumaresan, PhD,
Resolved Hepatitis B Virus Infection Is Not Associated with Worse Outcome after Allogeneic Hematopoietic Stem Cell Transplantation  Carlos A. Ramos, Rima.
by Shannon L. Maude, David T. Teachey, David L. Porter, and Stephan A
Comparison of High-Dose Gemcitabine, Busulfan and Melphalan (GEM/BU/MEL) and BEAM in Concurrent Patient Cohorts with Mature T-CELL NON-Hodgkin's Lymphoma.
Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond  Stanley R. Riddell, Michael C. Jensen, Carl.
Lymphocyte Recovery Predicts Outcomes in Cord Blood and T Cell–Depleted Haploidentical Stem Cell Transplantation  Stefan O. Ciurea, Victor Mulanovich,
Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia Patients  Mithun Vinod Shah, Rima M.
Dose Intensification of Busulfan in the Preparative Regimen is Associated with Improved Survival: A Phase I/II Controlled, Randomized Study  Simrit Parmar,
Molecular Therapy  Volume 21, Pages S247-S248 (May 2013)
Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation  Stefan O. Ciurea,
Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome 
CD34+ cell content of 126 341 cord blood units in the US inventory: implications for transplantation and banking by Juliet N. Barker, Jane Kempenich, Joanne.
Bigger, Stronger, Faster: Chimeric Antigen Receptor T Cells Are Olympic Killers by Paul J Neeson, Alexander James Davenport, Joseph A Trapani, Michael.
Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.
Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS:
Chimeric antigen receptor–modified T cells: CD19 and the road beyond
by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal
Results of Allogeneic Double Umbilical Cord Blood Transplantation for Relapsed and Refractory Hodgkin Lymphoma  Philip A. Thompson, MBBS, FRACP, FRCPA,
by Jennifer N. Brudno, and James N. Kochenderfer
Leukemia Stem Cells Are Characterized By CLEC12A Expression and Chemotherapy Refractoriness That Can be Overcome By Targeting with Chimeric Antigen Receptor.
Presentation transcript:

Adoptive Immunotherapy Following Umbilical Cord Blood Transplantation Using The Sleeping Beauty System and Artificial Antigen Presenting Cells To Generate Donor-Derived T Cells Expressing a CD19-Specific Chimeric Antigen Receptor by Partow Kebriaei, Helen Huls, Harjeet Singh, Simon Olivares, Matthew Figliola, Pappanaicken R Kumar, Bipulendu Jena, Rineka N Jackson, Tingting Liu, Ian K. McNiece, Gabriela Rondon, Perry Hackett, Richard E Champlin, Elizabeth J Shpall, and Laurence J N Cooper Blood Volume 122(21):4208-4208 November 15, 2013 ©2013 by American Society of Hematology

Specific lysis (Mean ± SEM, n=8) of CD19pos targets as compared to background lysis of CD19neg EL-4 (mouse T-cell line) by clinical-grade UCB-derived CD19-specific CAR+ T cells. Specific lysis (Mean ± SEM, n=8) of CD19pos targets as compared to background lysis of CD19neg EL-4 (mouse T-cell line) by clinical-grade UCB-derived CD19-specific CAR+ T cells. Helen Huls et al. Blood 2013;122:4208 ©2013 by American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.